Dickran Kazandjian is an Oncology physician affiliated with University of Miami. OpenAlex indexes 229 publications with 5,615 citations (h-index 34); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1120 NW 14th St Rm 828
Miami, FL 331362107
Telephone
305-243-5001Provider last certified this registry record 28 Jun 2022.
Clinical trials
- IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Sponsor: Dickran Kazandjian, MD
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Sponsor: University of Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20259 payments$21,226openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202512 payments$11,758openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.6%Thalidomide Analog68.3%Revlimid46%Lenalidomide43%Pomalyst11%Part D<11 patientsBCL-2 Inhibitor2.3%Venclexta100%Part D<11 patientsAnti-infectives
18.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.7%Valacyclovir100%Part D≥20 patientsShort-acting sulfonamides3%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsBlood & clotting
8.3%Factor Xa inhibitor8.3%Eliquis100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genomic Classification and Individualized Prognosis in Multiple Myeloma
Journal of Clinical Oncology
2024 - Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Current Oncology Reports
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”